Lipid Nanoparticle Library For Non-Viral Delivery Of mRNA And saRNA Towards Vaccine And Cell & Gene Therapy Applications


Recent FDA approval of ONPATTRO® by Alnylam, BioNTech/Pfizer and Moderna mRNA vaccine and the various clinical trials with mRNA-based drugs or vaccines have provided momentum to further develop LNP-based genetic medicine candidates. Efficient ionizable lipids (one of the important component of LNPs) are needed that are non-toxic, can effectively encapsulate nucleic acids, and can help with endosomal release. Scarcity of lipids that are suitable for vaccination, cell and gene therapy continue to be a problem in advancing many potential therapeutic/vaccine candidates to the clinic. PNI developed a proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene